XBiotech Inc.: Form 10-Q/A for the period ended Mar 31, 2015
Filed with the SEC on Jun 18, 2015 and accepted by EDGAR at Jun 18, 2015, 12:53 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2015-01-01 to 2015-03-31 | $6.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-01-01 to 2015-03-31 | −$8.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2015-01-01 to 2015-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-01-01 to 2015-03-31 | −$8.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-01-01 to 2015-03-31 | −$0.29 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2015-01-01 to 2015-03-31 | −$6.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2015-01-01 to 2015-03-31 | $571.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-03-31 | $52.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-03-31 | $53.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-03-31 | $58.7m | us-gaap:Assets |
| Current liabilities | At period end2015-03-31 | $3.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-03-31 | $3.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-03-31 | $54.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001171843-15-003499. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.